GH Research PLC Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.17next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly267.3MTarget: Sufficient to fund operations and Phase 3 trials through key readouts
GH001 Phase 2b TRD MADRS Reduction Quarterly-15.5Target: Statistically significant placebo-adjusted reduction in Phase 3
GH001 Phase 2b TRD 6-Month Remission Rate Quarterly73.0%Target: Maintain high durable remission in Phase 3 open-label extension
Watch Items
- FDA Alignment on Phase 3 Pivotal Program DesignTrigger: Final protocol agreement or Special Protocol Assessment (SPA) approvalAction: Initiate global Phase 3 clinical trials for GH001 in TRD
- Phase 1 Aerosol Delivery Device Trial (GH001-HV-106)Trigger: Completion of enrollment and positive safety/pharmacokinetic dataAction: Integrate proprietary aerosol device into the Phase 3 pivotal program
- IND Submission for GH002 (Intravenous Mebufotenin)Trigger: FDA clearance of IND applicationAction: Initiate Phase 2 clinical trials in psychiatric or neurological indications
Research as of 19 Jun 2026